Company intelligence / Profile preview
Eumentis Therapeutics
Boston, Massachusetts, United Stateseumentistx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Eumentis’s lead product EM-221—a best-in-class oral PDE10A inhibitor—has advanced to Phase 2 clinical trials targeting Tourette syndrome. Another candidate, EM-113 (a fast-off NMDA receptor antagonist), targets autism spectrum disorder and uses a proprietary biomarker-based patient selection approach. The company also has preclinical programs in traumatic brain injury and other CNS conditions. Clinical results are not yet published but the company has raised significant funding and received a Department of Defense award for TBI research
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (notably PDE10A inhibitors and NMDA receptor antagonists)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
U.S. Department of Defense grant for TBI research; no major pharma partnerships disclosed as of now
Beyond the preview
Go deeper on Eumentis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eumentis Therapeutics.